Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.

Roeloffzen EM, Monninkhof EM, Battermann JJ, van Roermund JG, Moerland MA, van Vulpen M.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):76-84. doi: 10.1016/j.ijrobp.2010.01.022. Epub 2010 Jun 3.

PMID:
20605364
2.

Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.

Roeloffzen EM, van Vulpen M, Battermann JJ, van Roermund JG, Saibishkumar EP, Monninkhof EM.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):737-44. doi: 10.1016/j.ijrobp.2010.06.009. Epub 2010 Oct 1.

PMID:
20888131
3.

Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.

Roeloffzen EM, Battermann JJ, van Deursen MJ, Monninkhof EM, Visscher MI, Moerland MA, van Vulpen M.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1072-9. doi: 10.1016/j.ijrobp.2010.03.009. Epub 2010 Jul 7.

PMID:
20615621
4.

Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy.

Thomas MD, Cormack R, Tempany CM, Kumar S, Manola J, Schneider L, Hurwitz MD, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):905-8.

PMID:
10863058
5.

The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.

Roeloffzen EM, Hinnen KA, Battermann JJ, Monninkhof EM, van Roermund JG, van Gellekom MP, Frank SJ, van Vulpen M.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1322-8. doi: 10.1016/j.ijrobp.2009.06.083. Epub 2009 Nov 24.

PMID:
19939578
6.

Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.

Mabjeesh NJ, Chen J, Stenger A, Matzkin H.

Urology. 2007 Sep;70(3):548-53.

PMID:
17905113
8.

Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?

Keyes M, Schellenberg D, Moravan V, McKenzie M, Agranovich A, Pickles T, Wu J, Liu M, Bucci J, Morris WJ.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):825-34.

PMID:
16458775
9.

Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.

Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M.

Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):453-60.

PMID:
11872292
10.

Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.

Salem N, Simonian-Sauve M, Rosello R, Alzieu C, Gravis G, Maraninchi D, Bladou F.

Radiother Oncol. 2003 Feb;66(2):159-65.

PMID:
12648787
11.

Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy.

Lee HK, Adams MT, Shi Q, Basillote J, Lamonica J, Miranda L, Motta J.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1445-9. doi: 10.1016/j.ijrobp.2009.04.008. Epub 2009 Jun 24.

PMID:
19553032
12.

Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.

Morton GC, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305. doi: 10.1016/j.ijrobp.2010.04.046. Epub 2010 Aug 12.

PMID:
20708853
13.

Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications.

Steggerda MJ, van der Poel HG, Moonen LM.

Brachytherapy. 2010 Oct-Dec;9(4):319-27. doi: 10.1016/j.brachy.2009.07.010. Epub 2010 Aug 6.

PMID:
20691644
14.

The dosimetry of prostate brachytherapy-induced urethral strictures.

Merrick GS, Butler WM, Tollenaar BG, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):461-8.

PMID:
11872293
15.

Long-term urinary quality of life after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):454-61.

PMID:
12738320
16.

Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.

Gómez-Iturriaga Piña A, Crook J, Borg J, Ma C.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):422-7. doi: 10.1016/j.ijrobp.2009.07.1723.

PMID:
20832665
17.

Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.

Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM.

Radiother Oncol. 2004 Oct;73(1):33-8.

PMID:
15465143
18.

Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.

Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):772-80. Epub 2005 Jun 20.

PMID:
15964707
19.

Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.

Hathout L, Folkert MR, Kollmeier MA, Yamada Y, Cohen GN, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):312-9. doi: 10.1016/j.ijrobp.2014.06.031.

PMID:
25304791
20.

Time course of prostatic edema post permanent seed implant determined by magnetic resonance imaging.

Sloboda RS, Usmani N, Pedersen J, Murtha A, Pervez N, Yee D.

Brachytherapy. 2010 Oct-Dec;9(4):354-61. doi: 10.1016/j.brachy.2009.09.008. Epub 2010 Jan 29.

PMID:
20116344

Supplemental Content

Support Center